.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practical Implications for New Data in Lung Cancer Systemic Therapy

EP. 1: CRT in Locally Advanced NSCLC

January 14th 2019

EP. 2: Chemotherapy Considerations in Locally Advanced NSCLC

January 14th 2019

EP. 3: Durvalumab After CRT in Locally Advanced NSCLC

January 14th 2019

EP. 4: EGFR and PD-L1 Testing in Locally Advanced NSCLC

January 14th 2019

EP. 5: Surgery and Locally Advanced NSCLC

January 14th 2019

EP. 6: Chemo + I-O in Frontline mNSCLC: PD-L1 TPS 1%-49%

January 14th 2019

EP. 7: Chemo + I-O in Frontline mNSCLC: PD-L1 TPS >50%

January 14th 2019

EP. 8: Combinations With Novel Agents for Metastatic NSCLC

January 14th 2019

EP. 9: TMB and Multiplex Testing in Metastatic NSCLC

January 14th 2019

EP. 10: NSCLC: Treating Progression After Chemo and I-O

January 14th 2019

EP. 11: Frontline Treatment for EGFR+ NSCLC

January 14th 2019

EP. 12: Treatment of EGFR+ NSCLC After Osimertinib

January 14th 2019

EP. 13: Systemic Therapy Vs Radiotherapy for Small Brain Mets

January 14th 2019

EP. 14: Treating Newly Diagnosed ALK+ NSCLC

January 14th 2019

EP. 15: Biopsy Considerations After Progression in ALK+ NSCLC

January 14th 2019

EP. 16: Sequencing Therapy in ALK+ NSCLC

January 14th 2019